BioCardia

BioCardia is a clinical-stage regenerative medicine company. The company's mission is to bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Its lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications, heart failure that develops after a heart attack and chronic myocardial ischemia.

BioCardia's second therapeutic platform, the CardiALLO™ Cell Therapy System, is an investigational culture expanded bone marrow derived allogenic or “off the shelf” cell therapy using neurokinin-1 receptor positive mesenchymal stem cells for the treatment of cardiac and pulmonary disease.

BioCardia has taken a new approach to addressing heart failure by introducing patient screening and efficient delivery to stem cell therapy, the company aims to increase the likelihood of treatment success, allowing more patients to return back to normal and the things they used to love.